Discover more from Alexander COVID News-Dr. Paul Elias Alexander's Newsletter
BREAKING: Judicial Watch FOIA: Pfizer/BioNTech Study Found Lipid Nanoparticles Materials Outside Injection Site in Test Animals; MATCHES the Japanese biodistribution findings
This supports what we have been saying all along, that the vaccine and its content leave the injection site (we were told it would not) & DANGEROUSLY enters the blood stream and goes all over the body
This report adds to the evidence of why we as people, citizens, have been very concerned and knew that these vaccines were never tested properly and especially so for safety.
The findings reported by Judicial Watch match the Japanese Pfizer biodistribution data from animals. If the lipid nano particles (LNP) go all over the body of the animals, then it more than likely does the same in humans, and if the LNP goes all over the body in humans, then it can be taken up by cells all over the body and the content, the mRNA (with the methyl-pseudo-uridine), can be translated to the spike protein all over the body (most certainly), churning out spike uncontrolled…this Judicial Watch piece of work is key and adds a damaging dimension…helps explain the myocarditis and CVST and all the ailments and death post mRNA vaccine. It’s the PEG in the LNP and the pseudo-uridine that are the culprits along with other chemicals/molecules added to stabilize and protect the LNP and mRNA and to deliver it….
“Judicial Watch announced today that it received 466 pages of records from the Department of Health and Human Services (HHS) regarding biodistribution studies and related data for the COVID-19 vaccines that show a key component of the vaccines developed by Pfizer/BioNTech, lipid nanoparticles (LNPs), were found outside the injection site, mainly the liver, adrenal glands, spleen and ovaries of test animals, eight to 48 hours after injection….
Judicial Watch also received 663 pages of records from HHS regarding biodistribution studies and related data for COVID-19 vaccines, which show that Johnson & Johnson relied on studies showing that vaccine DNA particles and injected virus particles were still present in test animals months after injection…
Judicial Watch obtained the records in response to a Freedom of Information Act (FOIA) lawsuit (Judicial Watch v. U.S. Department of Health and Human Services (No. 1:21-cv-02418)) filed after the Food and Drug Administration, the Centers for Disease Control and Prevention and the National Institute for Allergy and Infectious Disease failed to respond to a June 8, 2021, FOIA request for:
[A]ccess to biodistribution studies and related data for the Pfizer, Moderna, and Johnson & Johnson vaccines used to treat and/or prevent SARS-CoV-2 and/or COVID-19….
The Pfizer records include a report, which was approved in February 2021, on the animal trials on the distribution of the Pfizer COVID vaccine in rat subjects, in a section titled “Safety Pharmacology,” the report notes, “No safety pharmacology studies were conducted with BNT162b2 [the BioNTech vaccine] as they are not considered necessary for the development of vaccines according to the WHO guideline (WHO, 2005).” Similarly, under “Pharmacodynamic Drug Interactions,” is “Nonclinical studies evaluating pharmacodynamic drug interactions with BNT162b2 were not conducted as they are generally not considered necessary to support development and licensure of vaccine products for infectious diseases (WHO, 2005).”…
This Pfizer report notes that when lipid nanoparticles (LNPs) “with a comparable composition,” to that used in the Pfizer COVID vaccine were injected into rats, “Total recovery (% of injected dose) of LNP outside the injection site was greatest in the liver and was much less in the spleen, adrenal glands, and ovaries.” … “in summary” … “the LNP distributes to the liver.” In the detailed analysis, the report states, “Over 48 hours, the LNP distributed mainly to liver, adrenal glands, spleen and ovaries, with maximum concentrations observed at 8-48 hours post-dose. Total recovery (% of injected dose) of LNP, for combined male and female animals, outside of the injection site was greatest in the liver (up to 18%) …”…
This same Pfizer/BioNTech study notes “No genotoxicity studies are planned for BNT162b2 [the Pfizer/BioNTech COVID vaccine] as the components of the vaccine constructs are lipids and RNA and are not expected to have genotoxic potential (WHO, 2005).” Similarly, “Carcinogenicity studies with BNT162b2 have not been conducted as the components of the vaccine construct are lipids and RNA and are not expected to have carcinogenic or tumorigenic potential.”…
Also included in the Pfizer records is a report, approved in January 2021, titled “Pharmacokinetics Tabulated Summary.” A table in the report shows the biodistribution of lipid nanoparticles containing mRNA used in the vaccine using rats as the clinical trial subjects reports LNPs accumulating after 48 hours, especially in the lymph nodes, ovaries, small intestine and spleen….
a November 4, 2020, report submitted to the FDA regarding the Johnson & Johnson COVID vaccine, the authors discuss the 2007 New Zealand rabbit study in which adenovirus-vectored vaccine is trialed, but note that “No pharmacokinetic or biodistribution studies have been conducted with AD26.COV2.S specifically.”
The report notes that metabolism, excretion, and pharmacokinetic interactions with other drugs were not studied in this trial because they are “Not applicable to vaccines.” It is also noted that “biodistribution studies have not been conducted with Ad26.COV2.S.”